
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ALE1
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Alesta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
1cBio, Alesta Sign Global License for Small Molecule in Hypophosphatasia
Details : Alesta will develop, commercialize, and manufacture OC-1 (also known as ALE1), an orally active therapeutic candidate for hypophosphatasia (HPP).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 08, 2025
Lead Product(s) : ALE1
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Alesta Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
